about
Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arraysTranscriptional activators enhance polyadenylation of mRNA precursorsA Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cellsMenin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locusThe tumor suppressor Cdc73 functionally associates with CPSF and CstF 3' mRNA processing factorsMenin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitorsThe parafibromin tumor suppressor protein is part of a human Paf1 complexGenomic representations using concatenates of Type IIB restriction endonuclease digestion fragmentsRecurrent BRAF mutations in Langerhans cell histiocytosisGenomic analysis identifies association of Fusobacterium with colorectal carcinomaA landscape of driver mutations in melanomaMutational heterogeneity in cancer and the search for new cancer-associated genesIntegrative analysis of the melanoma transcriptomeMelanoma genome sequencing reveals frequent PREX2 mutationsExome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancerThe genomic complexity of primary human prostate cancerDissecting the genomic complexity underlying medulloblastomaInitial genome sequencing and analysis of multiple myelomaSomatic mutations affect key pathways in lung adenocarcinomaThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPCharacterizing the cancer genome in lung adenocarcinoma.Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1The multifunctional protein p54nrb/PSF recruits the exonuclease XRN2 to facilitate pre-mRNA 3' processing and transcription terminationOncogenic transformation by inhibitor-sensitive and -resistant EGFR mutantsAllele-specific amplification in cancer revealed by SNP array analysisChromothripsis from DNA damage in micronuclei.Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor SensitivityStructural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung CancerEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.Activating mutations in ALK provide a therapeutic target in neuroblastoma.Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma.HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.Oncogenic RIT1 mutations in lung adenocarcinoma.
P50
Q21563517-5B386D14-DFBA-4637-BE63-CD4642EE328EQ24293440-1207BB02-01CB-4F44-A564-0C72DE988E65Q24294219-13427F8E-09AC-416C-AA51-BB2F81DC11CCQ24302462-ABD8EE91-F025-44A2-829A-94513DC2DC9CQ24313196-48835E8B-4F7C-4358-93C5-D8958DF0C427Q24315774-41F0259D-6C9B-42CC-B4EB-E1244D523307Q24337658-AD3B37E0-7F0B-4BE3-8ED4-D37097DF7B4BQ24557571-4476F84F-A7AA-49C5-884C-2744430945BFQ24562228-375CCDC6-2BD8-41F7-B231-330681148A10Q24594344-37658A02-1169-44FA-BDC3-10139DF60902Q24603176-7294F7DE-E280-404A-B40C-1922E11C2BB1Q24603357-4A1BAE63-3FA5-4EBC-96E6-54EC94D6FD16Q24606956-87FAF979-EFB9-458E-ACE9-D1C2D0E4A5FDQ24608060-165DA74B-270E-4AF3-B180-108A9B06886CQ24610463-18989A77-BEDB-4ADC-8145-B3F2D91AE1A7Q24616117-F7B6F708-092D-43E5-A1E7-7301D9F17C93Q24617949-E4DC74D2-E172-4C8E-808A-6730A5CC2952Q24621907-0E1298B6-0178-4D4F-9AC5-6F60CA903F02Q24629117-0991F375-C86B-49C1-961A-1454E6A522C3Q24648102-3CEF71A3-29FA-4357-A9AB-56F5157982F2Q24649549-2BD9A5CD-08DF-4336-8732-06E2B636A94BQ24649926-B867FDEC-0AE2-4F93-9128-43134B8989A5Q24651548-274BEC21-5660-4249-AA64-CE5789EDBD94Q24671920-37180B51-3E9F-4B73-920F-CFCBF3856DCCQ24810573-56341AA0-F5AA-41A3-954E-F0F1660F964EQ24811573-06A442D6-3D74-436D-975E-5B7B3A537FFEQ27316519-3276B30B-13F7-40A3-A2BD-F5A3B23F3507Q27644014-844C9FDB-A31F-4C07-A726-136DCC95BBD2Q27680966-B5B54B12-86A8-4E73-A809-D5A8ED5D3B62Q27824812-2CDFAD4D-B9CB-43AC-8F9B-B963EF0704AFQ27824829-B4D3D1F9-E052-4878-9D6D-67C38E93D0DEQ27851394-9AEA0E0A-A4FE-4B7B-A3AD-8FE3CAF6A30DQ27851440-E0FD89D7-5F66-4853-A999-B705B0CF08DFQ27851452-6B09FCB9-B410-489A-A0B8-B7E88D04C9BAQ27851458-3A2BA370-A3F8-4B8B-A80C-1204BCBDB440Q27851461-9341107D-28C7-4AAA-99E0-1E085798EE4BQ27851628-2B473556-E5F9-4B5B-80E1-A84444033486Q27851654-3E9A2918-01C6-4533-BB7C-D647534F018CQ27851720-1F685218-D4DE-4A59-AA3D-F6F6FB6BFD40Q27852800-AC422B77-773D-4781-B182-77F0710AB5A5
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Matthew Meyerson
@ast
Matthew Meyerson
@en
Matthew Meyerson
@es
Matthew Meyerson
@fr
Matthew Meyerson
@nl
Matthew Meyerson
@sl
type
label
Matthew Meyerson
@ast
Matthew Meyerson
@en
Matthew Meyerson
@es
Matthew Meyerson
@fr
Matthew Meyerson
@nl
Matthew Meyerson
@sl
altLabel
Matthew L Meyerson
@en
prefLabel
Matthew Meyerson
@ast
Matthew Meyerson
@en
Matthew Meyerson
@es
Matthew Meyerson
@fr
Matthew Meyerson
@nl
Matthew Meyerson
@sl
P106
P21
P31
P496
0000-0002-9133-8108